Hearing Loss in Cisplatin Treated Patients

David Freyer, DO
Published Online: May 1, 2017

David Freyer, DO, of the Children's Hospital of Los Angeles and professor of pediatrics at Keck School of Medicine, University of Southern California, explains the mechanisms by which hearing loss can occur in children (and adults) treated with cisplatin, a chemotherapy agent commonly used in oncology. 
As Dr Freyer explains in this video taken during the ASPHO's 30th Annual Meeting in Montreal, Canada, the ototoxicity can be particular harmful to the survivors of pediatric cancer.
Sodium thiosulfate (STS) is a water-soluble thiol compound and acts as a chemical reducing agent. Administration of STS may protect against platinum-induced ototoxicity, as it has been shown in animal models and in patients.

Latest Articles
Positive initial results from a Phase 1A clinical trial evaluating setmelanotide (RM-492) for the treatment of rare genetic disorders of obesity were reported.
He’s a patient, an educator, and an advocate. Huntington's Disease patient and Bellingham researcher Jeff Carroll is a triple threat.
Dr Gavin Rumbaugh, PhD of Scripps Florida Research Institute was awarded an NIMH-funded grant for the therapeutic development of Syngap1.
Cooper sits down with RDR to talk about A4250, why it’s so important to children with PFIC, and just how Albireo prioritizes treatment for rare diseases.
$vacMongoViewPlus$ $vAR$